Medtronic
-
Jim Cramer Calls Medtronic (MDT) a "Quandary" as Growth Surges and Diabetes Exit Nears
On the September 8 episode of Mad Money, Jim Cramer described medical device company Medtronic (MDT) as a "quandary," noting its strong organic growth and the planned separation of its diabetes divisi
-
Motley Fool Analysis: Medtronic (MDT) Stock Is a Buy Due to Record FY2026 Revenue, 49 Consecutive Years of Dividend Growth, and Attractive Valuation
Motley Fool analysis indicates that medical device giant Medtronic (MDT) achieved an 8.4% revenue growth to $36.4 billion in fiscal year 2026 (ending this April), marking its highest growth rate in a
-
Medtronic Raises FY2027 Outlook After Q1 Revenue Jumps 13.7% to $9.8B, Adjusted EPS Beats Expectations
Medtronic reported fiscal 2027 first-quarter revenue of $9.8 billion, a 13.7% increase, and adjusted EPS of $1.45, both exceeding expectations. The medical-device maker now projects full-year organic
-
Analysis suggests Tenet Healthcare offers stronger immediate earnings growth, while Medtronic presents a more diversified long-term opportunity
The analysis highlights that Tenet Healthcare's latest earnings show adjusted diluted EPS rose 52.2% year-over-year to $6.12, with net operating revenue up 6.8% to $5.63 billion, and hospital adjusted
-
Jim Cramer Calls Medtronic (MDT) a "Quandary" as Growth Surges and Diabetes Exit Nears
On the September 8 episode of Mad Money, Jim Cramer described medical device company Medtronic (MDT) as a "quandary," noting its strong organic growth and the planned separation of its diabetes divisi
-
Motley Fool Analysis: Medtronic (MDT) Stock Is a Buy Due to Record FY2026 Revenue, 49 Consecutive Years of Dividend Growth, and Attractive Valuation
Motley Fool analysis indicates that medical device giant Medtronic (MDT) achieved an 8.4% revenue growth to $36.4 billion in fiscal year 2026 (ending this April), marking its highest growth rate in a
-
Medtronic Raises FY2027 Outlook After Q1 Revenue Jumps 13.7% to $9.8B, Adjusted EPS Beats Expectations
Medtronic reported fiscal 2027 first-quarter revenue of $9.8 billion, a 13.7% increase, and adjusted EPS of $1.45, both exceeding expectations. The medical-device maker now projects full-year organic
-
Analysis suggests Tenet Healthcare offers stronger immediate earnings growth, while Medtronic presents a more diversified long-term opportunity
The analysis highlights that Tenet Healthcare's latest earnings show adjusted diluted EPS rose 52.2% year-over-year to $6.12, with net operating revenue up 6.8% to $5.63 billion, and hospital adjusted
- No data
Medtronic
24H Trending
-
1
BitMart Exchange Has Ceased Operations: A Review of Perpetual Contract Services and Platform Status
-
2
Polkadot (DOT) Ecosystem Expansion: New Projects, Core Upgrades, and Tokenomics Transformation
-
3
PROP Coin Value Analysis: Propbase (PROPS) Project and Investment Outlook
-
4
China's Cryptocurrency Regulatory Policies and a Global Overview of Trading Platforms
-
5
Securitize is bringing tokenized shares of giants like Apple, NVIDIA, and Tesla to Solana, with plans for listing on the New York Stock Exchange.
-
6
Casper (CSPR) Token Analysis: The State of Enterprise Blockchains and Market Considerations
-
7
Major Global Cryptocurrency Exchanges: Market Landscape, Services, and Compliance Trends
-
8
In-depth Analysis of CAKE Token Market Capitalization Trends: PancakeSwap Ecosystem and Deflationary Mechanism
-
9
AI Arms Race "Overwhelms" US Bond Market: SpaceX, Broadcom, Oracle Seek Over $150 Billion in Financing Within a Week, Pressuring Treasury Yields Upward
-
10
DCR Coin: Decred Token Trading Platforms and Purchase Guide
Markets Today
Recommended Reading








